Cumberland Pharmaceuticals (NASDAQ:CPIX) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Cumberland Pharmaceuticals (NASDAQ:CPIX) in a research report sent to investors on Tuesday morning. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Cumberland Pharmaceuticals Price Performance

CPIX opened at $2.50 on Tuesday. The company has a 50 day moving average of $1.98 and a two-hundred day moving average of $1.55. Cumberland Pharmaceuticals has a 52-week low of $1.04 and a 52-week high of $3.93. The company has a quick ratio of 0.99, a current ratio of 1.13 and a debt-to-equity ratio of 0.41. The company has a market cap of $35.10 million, a P/E ratio of -3.25 and a beta of 0.13.

Cumberland Pharmaceuticals (NASDAQ:CPIX) last released its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter. Cumberland Pharmaceuticals had a negative net margin of 29.54% and a negative return on equity of 9.50%. The company had revenue of $9.09 million during the quarter.

Cumberland Pharmaceuticals Company Profile

Cumberland Pharmaceuticals Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; Sancuso, an injection for the treatment of chemotherapy treatment; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections.